Amarin (AMRN) To Resume Trading at 7:15AM ET
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin Corporation plc (Nasdaq: AMRN) will resume trading at 7:15AM ET following FDA approval of Vascepa for severe hypertriglyceridemia.
Amarin is awaiting a decision from FDA as to whether Vascepa will be granted five-year new chemical entity (NCE) or three-year new product marketing exclusivity.
Amarin is awaiting a decision from FDA as to whether Vascepa will be granted five-year new chemical entity (NCE) or three-year new product marketing exclusivity.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Innate Pharma completes enrollment in Phase 1 IPH4502 ADC study
- Personalis, Inc. (PSNL) Halted News Pending
- Belite Bio reports Phase 3 tinlarebant data at ASRS meeting
Create E-mail Alert Related Categories
FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
